BACKGROUND Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture, and bioresorbable polymers. Whether these advancements improve long-term clinical safety and efficacy has been inconsistent in prior studies.
Vascular, Santa Clara, California) (7) . At 1 year, significant differences were observed favoring treatment with BP SES regarding the primary endpoint of target lesion failure (TLF) (6.0% vs. 10.0%; p ¼ 0.04) and target vessel-related myocardial infarction (MI) (5.0% vs. 8.0%; p ¼ 0.02) (8) . Further, in a pooled analysis with 2 additional randomized trials comparing these stents (9, 10) , the Bayesian posterior probability of noninferiority for BP SES was 100%, and the posterior probability of superiority was 97%. Detailed descriptions of the study design, inclusion and exclusion criteria, methods, and 1-year results of the BIOFLOW V trial have been previously reported (7, 8) . Briefly, BIOFLOW V (NCT02389946) is a prospective at 1 year). The difference in TLF was driven principally by a significant difference in target vesselrelated MI (5.3% vs. 9.5%; p ¼ 0.01) ( Table 2 ) in addition to significantly lower ischemia-driven TLR in Log-rank p = 0.72 (0 -360 days); p = 0.01 (361 -720 days) 
